Key result
Transvalvular microaxial flow pump yields ~1.1 additional QALYs at acceptable cost-effectiveness over standard care.
Why the study?
In infarct-related cardiogenic shock, a transvalvular microaxial flow pump reduced 180 day mortality but increased adverse events, and its cost-effectiveness from the perspective of German statutory health insurance needed evaluation.
Is a transvalvular microaxial flow pump cost-effective for patients with infarct-related cardiogenic shock from the perspective of German statutory health insurance?
Is a transvalvular microaxial flow pump cost-effective for patients with infarct-related cardiogenic shock from the perspective of German statutory health insurance?
In the German statutory health insurance system, a transvalvular microaxial flow pump for infarct-related cardiogenic shock is likely cost-effective at €36,083 per QALY gained, provided acute payment differences remain below €14,703.
Answers are grounded in this paper and cite their sources.
May support QALY gains with the pump in cardiogenic shock; hypothesis-generating for cost-effectiveness and safety.
In infarct-related cardiogenic shock, a transvalvular microaxial flow pump reduced 180 day mortality but increased adverse events. We evaluated its cost-effectiveness for German statutory health insurance (SHI). A cohort state-transition model compared the two strategies over a lifetime horizon: a 180 day acute phase from trial outcomes, and chronic states with or without heart failure. Costs and quality-adjusted life-years (QALYs) were discounted at 3% in 2023 euros. Parameter uncertainty was assessed probabilistically and unresolved acute payments by threshold analysis. The pump yielded 1.06 additional QALYs at incremental costs of €38,121 and an incremental cost-effectiveness ratio of €36,083 per QALY. At an illustrative willingness-to-pay threshold of €50,000 per QALY, the probability of cost-effectiveness was 86%. Bleeding 21.8 versus 11.9%, limb ischemia 5.6 versus 1.1%. Due to the lack of arm-specific case-group data, the reference analysis assumed no between-arm difference in acute payments; net monetary benefit (NMB) remained positive below €14,703. Under the reference assumptions, the pump may be cost-effective for German SHI, conditional on an unresolved acute payment difference in which arm-specific routine billing data could be determined. https://www.clinicaltrials.gov identifier: NCT01633502. This economic analysis was not performed separately.
No takes yet. Share an insight, caveat, or question.
Boettger et al. (2026) studied Infarct-related cardiogenic shock. Transvalvular microaxial flow pump vs. Standard care without transvalvular microaxial flow pump was evaluated on Incremental cost-effectiveness ratio (ICER) and incremental quality-adjusted life-years (QALYs) over a lifetime horizon (ICER €36,083 per QALY (+1.06 QALYs, +€38,121)). A transvalvular microaxial flow pump yielded 1.06 additional QALYs at an incremental cost of €38,121 (ICER €36,083/QALY), with an 86% probability of cost-effectiveness at €50,000/QALY.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: